Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study

Lakhmir S Chawla, Laurence Busse, Ermira Brasha-Mitchell, Danielle Davison, Jacqueline Honiq, Ziyad Alotaibi, Michael G Seneff, Lakhmir S Chawla, Laurence Busse, Ermira Brasha-Mitchell, Danielle Davison, Jacqueline Honiq, Ziyad Alotaibi, Michael G Seneff

Abstract

Introduction: Patients with distributive shock who require high dose vasopressors have a high mortality. Angiotensin II (ATII) may prove useful in patients who remain hypotensive despite catecholamine and vasopressin therapy. The appropriate dose of parenteral angiotensin II for shock is unknown.

Methods: In total, 20 patients with distributive shock and a cardiovascular Sequential Organ Failure Assessment score of 4 were randomized to either ATII infusion (N =10) or placebo (N =10) plus standard of care. ATII was started at a dose of 20 ng/kg/min, and titrated for a goal of maintaining a mean arterial pressure (MAP) of 65 mmHg. The infusion (either ATII or placebo) was continued for 6 hours then titrated off. The primary endpoint was the effect of ATII on the standing dose of norepinephrine required to maintain a MAP of 65 mmHg.

Results: ATII resulted in marked reduction in norepinephrine dosing in all patients. The mean hour 1 norepinephrine dose for the placebo cohort was 27.6 ± 29.3 mcg/min versus 7.4 ± 12.4 mcg/min for the ATII cohort (P =0.06). The most common adverse event attributable to ATII was hypertension, which occurred in 20% of patients receiving ATII. 30-day mortality for the ATII cohort and the placebo cohort was similar (50% versus 60%, P =1.00).

Conclusion: Angiotensin II is an effective rescue vasopressor agent in patients with distributive shock requiring multiple vasopressors. The initial dose range of ATII that appears to be appropriate for patients with distributive shock is 2 to 10 ng/kg/min.

Trial registration: Clinicaltrials.gov NCT01393782. Registered 12 July 2011.

Figures

Figure 1
Figure 1
Study drug titration protocol. NorEpi, norepinephrine; MAP, mean arterial pressure.
Figure 2
Figure 2
Patient flow diagram.
Figure 3
Figure 3
Changes in norepinephrine dose with concurrent angiotensin II. AT-II arm, angiotensin-II arm; Angio dose, angiotensin-II dose.

References

    1. Vincent JL, De Backer D. Circulatory shock. N Engl J Med. 2013;369:1726–1734. doi: 10.1056/NEJMra1208943.
    1. Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J, CAT Study investigators A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34:2226–2234. doi: 10.1007/s00134-008-1219-0.
    1. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol. 1985;17:291–306. doi: 10.1016/S0022-2828(85)80130-9.
    1. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D'Egidio A, D'Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310:1683–1691. doi: 10.1001/jama.2013.278477.
    1. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, VASST Investigators Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–887. doi: 10.1056/NEJMoa067373.
    1. Basso N, Terragno NA. History about the discovery of the renin-angiotensin system. Hypertension. 2001;38:1246–1249. doi: 10.1161/hy1201.101214.
    1. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663–670. doi: 10.1016/j.cardiores.2003.11.037.
    1. Jackson T, Corke C, Agar J. Enalapril overdose treated with angiotensin infusion. Lancet. 1993;341:703. doi: 10.1016/0140-6736(93)90479-Z.
    1. Trilli LE, Johnson KA. Lisinopril overdose and management with intravenous angiotensin II. Ann Pharmacother. 1994;28:1165–1168.
    1. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710. doi: 10.1007/BF01709751.
    1. Newby DE, Lee MR, Gray AJ, Boon NA. Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol. 1995;40:103–104. doi: 10.1111/j.1365-2125.1995.tb04546.x.
    1. Wray GM, Coakley JH. Severe septic shock unresponsive to noradrenaline. Lancet. 1995;346:1604. doi: 10.1016/S0140-6736(95)91933-3.
    1. Whiteley SM, Dade JP. Treatment of hypotension in septic shock. Lancet. 1996;347:622. doi: 10.1016/S0140-6736(96)91324-0.
    1. Ryding J, Heslet L, Hartvig T, Jonsson V. Reversal of ‘refractory septic shock’ by infusion of amrinone and angiotensin II in an anthracycline-treated patient. Chest. 1995;107:201–203. doi: 10.1378/chest.107.1.201.
    1. Thomas VL, Nielsen MS. Administration of angiotensin II in refractory septic shock. Crit Care Med. 1991;19:1084–1086. doi: 10.1097/00003246-199108000-00020.
    1. Yunge M, Petros A. Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child. 2000;82:388–389. doi: 10.1136/adc.82.5.388.
    1. Correa TD, Jeger V, Pereira AJ, Takala J, Djafarzadeh S, Jakob SM. Angiotensin II in Septic Shock: Effects on Tissue Perfusion, Organ Function, and Mitochondrial Respiration in a Porcine Model of Fecal Peritonitis. Crit Care Med. 2014;42:e550–e559. doi: 10.1097/CCM.0000000000000397.
    1. Wan L, Langenberg C, Bellomo R, May CN. Angiotensin II in experimental hyperdynamic sepsis. Crit Care. 2009;13:R190. doi: 10.1186/cc8185.
    1. Goldsmith SR, Hasking GJ. Effect of a pressor infusion of angiotensin II on sympathetic activity and heart rate in normal humans. Circ Res. 1991;68:263–268. doi: 10.1161/01.RES.68.1.263.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren